Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2024
0mins
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 43.190
Low
42.00
Averages
54.67
High
70.00
Current: 43.190
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UPS Invests $48 Million to Expand Cold Chain Logistics
- Cold Chain Investment: UPS has announced a $48 million investment in 27 temperature-controlled facilities aimed at enhancing its competitiveness in healthcare logistics to meet the surging demand for pharmaceuticals and biologics.
- Market Growth Potential: The demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate, reaching a market value of approximately $39.1 billion by 2033, positioning UPS to capitalize on this rapidly expanding market with its investment.
- Enhanced Cold Chain Capabilities: UPS's global cross-dock facilities will strengthen its end-to-end cold chain capabilities, ensuring critical treatments are delivered safely and reliably to patients worldwide, reflecting the company's deep commitment to healthcare logistics.
- Revenue Growth Highlights: UPS's healthcare revenue surpassed $3 billion for the first time in Q1 2023, indicating a continuous increase in market share in this sector, further solidifying its position as an industry leader.
See More
UPS Invests $48 Million to Enhance Healthcare Logistics
- Investment Scale: UPS announces a $48 million investment to enhance 27 temperature-controlled facilities, reflecting the company's focus on the healthcare sector and its potential for future growth.
- Facility Optimization: These facilities, located across the Americas, Europe, and Asia, are designed for transporting temperature-sensitive shipments, enhancing UPS's competitiveness in pharmaceuticals and ensuring the safe and reliable delivery of critical treatments.
- Market Outlook: According to market reports, the demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033, reaching a market value of approximately $39.1 billion, positioning UPS favorably in this rapidly expanding market.
- Strategic Commitment: UPS executives state that this investment aims not only to enhance cold-chain capabilities but also to support innovative treatments and diagnostics, improving patient outcomes and further solidifying its market share in healthcare logistics.
See More
HIMS CMO Plans to Sell Shares Amid Positive Market Trends
- Share Sale Plan: Chief Medical Officer Patrick Carroll filed to sell 23,726 shares worth approximately $830,000, which may impact short-term market confidence in HIMS, despite the stock rising 36% in June.
- Wearable Integration: CEO Andrew Dudum announced that the integration of Oura Ring is coming soon, indicating a strategic push for HIMS in wearable connectivity aimed at enhancing user experience and medical service capabilities on the platform.
- Wall Street Optimism: Barclays raised HIMS's price target from $29 to $39, anticipating significant revenue and EBITDA acceleration in the second half of 2026, reflecting increased market confidence in the company's future growth.
- Positive Market Sentiment: On Stocktwits, retail sentiment for HIMS was bullish, with a 388% surge in message volume over 24 hours, indicating investor optimism regarding the company's efforts to expand its customer base.
See More
Novo Nordisk Launches Wegovy Pill, Revolutionizing Obesity Treatment
- Intensifying Market Competition: Novo Nordisk's Wegovy pill has quickly reached three million prescriptions, indicating consumer preference for oral medications, despite competition from Eli Lilly's new drug Foundayo, which appears less effective and faces a tougher market introduction.
- Transition Year Challenges: Novo Nordisk's stock has plummeted 70% from its 2024 highs, with the company warning of a difficult 2026 due to drug price reductions in the U.S. and generic competition in India, leading to a bearish sentiment among investors in the short term.
- Long-Term Growth Potential: Despite the uncertain short-term outlook, Novo Nordisk anticipates accelerated growth as demand for GLP-1 drugs increases, particularly with the rapid uptake of the Wegovy pill indicating market acceptance and potential for future expansion.
- Attractive Investment Opportunity: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk presents a compelling value proposition for income-focused investors looking for growth opportunities in the pharmaceutical sector.
See More
Novo Nordisk's Comeback in the GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy pill has quickly reached three million prescriptions, indicating strong demand in the weight-loss drug market, despite competition from Eli Lilly's more effective drugs, suggesting a growing preference for oral medications.
- Pricing Strategy Adjustment: Novo Nordisk has agreed to lower drug prices in the U.S. market and faces generic competition in India, a strategy aimed at addressing potential difficulties in 2026; despite a 70% stock price drop in the short term, long-term growth potential remains.
- Shift in Investor Focus: Although Wall Street's confidence in Novo Nordisk has waned, with concerns about its future, the company believes growth will accelerate as demand for GLP-1 drugs increases, indicating that the market may be underestimating its value and growth potential.
- Attracting Income Investors: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk appeals to income-focused investors, highlighting its long-term opportunities in the weight-loss drug market.
See More
Novo Nordisk's Wegovy Pill Hits 3 Million Prescriptions Amid Market Challenges
- Drug Innovation: Novo Nordisk's Wegovy pill has quickly gained market traction, reaching 3 million prescriptions, indicating a strong consumer preference for oral medications, which could further enhance the company's market share in the GLP-1 space.
- Intensifying Competition: While Novo Nordisk leads in the GLP-1 drug market, competitor Eli Lilly has launched the oral drug Foundayo, which, despite being less effective, poses a threat to Novo Nordisk, particularly in terms of market education and consumer acceptance.
- Negative Market Reaction: Novo Nordisk's stock has fallen 70% from its 2024 highs, and although it faces short-term challenges, the company anticipates long-term growth potential as demand for GLP-1 drugs increases, especially with drug price reductions.
- Investment Opportunity Assessment: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk may attract income-focused investors, despite the market's pessimistic outlook on its short-term performance.
See More
UPS Invests $48 Million to Expand Cold Chain Logistics
- Cold Chain Investment: UPS has announced a $48 million investment in 27 temperature-controlled facilities aimed at enhancing its competitiveness in healthcare logistics to meet the surging demand for pharmaceuticals and biologics.
- Market Growth Potential: The demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate, reaching a market value of approximately $39.1 billion by 2033, positioning UPS to capitalize on this rapidly expanding market with its investment.
- Enhanced Cold Chain Capabilities: UPS's global cross-dock facilities will strengthen its end-to-end cold chain capabilities, ensuring critical treatments are delivered safely and reliably to patients worldwide, reflecting the company's deep commitment to healthcare logistics.
- Revenue Growth Highlights: UPS's healthcare revenue surpassed $3 billion for the first time in Q1 2023, indicating a continuous increase in market share in this sector, further solidifying its position as an industry leader.
See More
UPS Invests $48 Million to Enhance Healthcare Logistics
- Investment Scale: UPS announces a $48 million investment to enhance 27 temperature-controlled facilities, reflecting the company's focus on the healthcare sector and its potential for future growth.
- Facility Optimization: These facilities, located across the Americas, Europe, and Asia, are designed for transporting temperature-sensitive shipments, enhancing UPS's competitiveness in pharmaceuticals and ensuring the safe and reliable delivery of critical treatments.
- Market Outlook: According to market reports, the demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033, reaching a market value of approximately $39.1 billion, positioning UPS favorably in this rapidly expanding market.
- Strategic Commitment: UPS executives state that this investment aims not only to enhance cold-chain capabilities but also to support innovative treatments and diagnostics, improving patient outcomes and further solidifying its market share in healthcare logistics.
See More
HIMS CMO Plans to Sell Shares Amid Positive Market Trends
- Share Sale Plan: Chief Medical Officer Patrick Carroll filed to sell 23,726 shares worth approximately $830,000, which may impact short-term market confidence in HIMS, despite the stock rising 36% in June.
- Wearable Integration: CEO Andrew Dudum announced that the integration of Oura Ring is coming soon, indicating a strategic push for HIMS in wearable connectivity aimed at enhancing user experience and medical service capabilities on the platform.
- Wall Street Optimism: Barclays raised HIMS's price target from $29 to $39, anticipating significant revenue and EBITDA acceleration in the second half of 2026, reflecting increased market confidence in the company's future growth.
- Positive Market Sentiment: On Stocktwits, retail sentiment for HIMS was bullish, with a 388% surge in message volume over 24 hours, indicating investor optimism regarding the company's efforts to expand its customer base.
See More
Novo Nordisk Launches Wegovy Pill, Revolutionizing Obesity Treatment
- Intensifying Market Competition: Novo Nordisk's Wegovy pill has quickly reached three million prescriptions, indicating consumer preference for oral medications, despite competition from Eli Lilly's new drug Foundayo, which appears less effective and faces a tougher market introduction.
- Transition Year Challenges: Novo Nordisk's stock has plummeted 70% from its 2024 highs, with the company warning of a difficult 2026 due to drug price reductions in the U.S. and generic competition in India, leading to a bearish sentiment among investors in the short term.
- Long-Term Growth Potential: Despite the uncertain short-term outlook, Novo Nordisk anticipates accelerated growth as demand for GLP-1 drugs increases, particularly with the rapid uptake of the Wegovy pill indicating market acceptance and potential for future expansion.
- Attractive Investment Opportunity: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk presents a compelling value proposition for income-focused investors looking for growth opportunities in the pharmaceutical sector.
See More
Novo Nordisk's Comeback in the GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy pill has quickly reached three million prescriptions, indicating strong demand in the weight-loss drug market, despite competition from Eli Lilly's more effective drugs, suggesting a growing preference for oral medications.
- Pricing Strategy Adjustment: Novo Nordisk has agreed to lower drug prices in the U.S. market and faces generic competition in India, a strategy aimed at addressing potential difficulties in 2026; despite a 70% stock price drop in the short term, long-term growth potential remains.
- Shift in Investor Focus: Although Wall Street's confidence in Novo Nordisk has waned, with concerns about its future, the company believes growth will accelerate as demand for GLP-1 drugs increases, indicating that the market may be underestimating its value and growth potential.
- Attracting Income Investors: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk appeals to income-focused investors, highlighting its long-term opportunities in the weight-loss drug market.
See More
Novo Nordisk's Wegovy Pill Hits 3 Million Prescriptions Amid Market Challenges
- Drug Innovation: Novo Nordisk's Wegovy pill has quickly gained market traction, reaching 3 million prescriptions, indicating a strong consumer preference for oral medications, which could further enhance the company's market share in the GLP-1 space.
- Intensifying Competition: While Novo Nordisk leads in the GLP-1 drug market, competitor Eli Lilly has launched the oral drug Foundayo, which, despite being less effective, poses a threat to Novo Nordisk, particularly in terms of market education and consumer acceptance.
- Negative Market Reaction: Novo Nordisk's stock has fallen 70% from its 2024 highs, and although it faces short-term challenges, the company anticipates long-term growth potential as demand for GLP-1 drugs increases, especially with drug price reductions.
- Investment Opportunity Assessment: With a price-to-earnings ratio of 10x, significantly lower than Eli Lilly's 40x, and a 4.1% dividend yield, Novo Nordisk may attract income-focused investors, despite the market's pessimistic outlook on its short-term performance.
See More
